Eledon Pharmaceuticals, Inc. 公布了其候选药物Tegoprubart在一项由研究者发起的胰岛细胞移植临床试验中获得的最新数据。该试验在芝加哥大学医学院进行，旨在评估Tegoprubart用于治疗1型糖尿病患者的潜力。
此次数据更新提供了关于药物安全性、耐受性以及对移植胰岛功能影响的进一步信息。研究结果有望为Tegoprubart在调节免疫反应、保护移植胰岛免受排斥方面的作用机制提供更深入的见解。1型糖尿病是一种自身免疫性疾病，患者体内产生胰岛素的细胞被免疫系统破坏，而胰岛移植旨在恢复机体的胰岛素生成能力。Tegoprubart作为一种研究性疗法，其目标是通过特定的免疫调节途径，为移植的胰岛细胞创造一个更有利的存活环境。
公司表示，这些来自早期临床研究的数据，将用于指导Tegoprubart后续的临床开发计划，并为其在器官移植和自身免疫性疾病领域的应用潜力提供支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.